Zymeworks Inc. (NYSE:ZYME) to Post Q1 2025 Earnings of ($0.43) Per Share, HC Wainwright Forecasts

Zymeworks Inc. (NYSE:ZYME) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Zymeworks in a note issued to investors on Tuesday, June 18th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.43) for the quarter. HC Wainwright has a “Neutral” rating and a $10.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS and Q4 2025 earnings at ($0.48) EPS.

A number of other brokerages have also recently commented on ZYME. Wells Fargo & Company reduced their price objective on Zymeworks from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Citigroup reduced their price objective on Zymeworks from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, May 3rd.

Zymeworks Price Performance

NYSE ZYME opened at $8.52 on Wednesday. The business has a 50 day simple moving average of $8.86 and a 200 day simple moving average of $10.01. Zymeworks has a one year low of $6.01 and a one year high of $13.14. The stock has a market capitalization of $602.45 million, a P/E ratio of -4.76 and a beta of 1.18.

Zymeworks (NYSE:ZYME) last released its earnings results on Thursday, May 2nd. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.11). Zymeworks had a negative return on equity of 28.37% and a negative net margin of 249.63%. The business had revenue of $10.03 million for the quarter, compared to analyst estimates of $17.98 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Gladius Capital Management LP lifted its holdings in shares of Zymeworks by 36.5% in the third quarter. Gladius Capital Management LP now owns 3,940 shares of the company’s stock valued at $25,000 after purchasing an additional 1,053 shares in the last quarter. AlphaMark Advisors LLC purchased a new position in shares of Zymeworks in the first quarter valued at $32,000. New York State Teachers Retirement System purchased a new position in Zymeworks during the fourth quarter worth about $50,000. AJOVista LLC purchased a new position in Zymeworks during the fourth quarter worth about $66,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in Zymeworks during the third quarter worth about $80,000. Institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.